Surrozen (SRZN) Non Operating Income (2020 - 2021)

Surrozen (SRZN) posted quarterly Non Operating Income of -$328000.0 for Q3 2021, up 87.06% quarter-over-quarter from -$2.5 million in Q2 2021.

Analysis

Surrozen (SRZN) Non Operating Income (2020 - 2021) Analysis & Trends

Surrozen's Non Operating Income history runs 2 years deep, the most recent figure standing at -$328000.0 for Q3 2021.

In Q3 2021, Non Operating Income changed N/A year-over-year to -$328000.0; the TTM figure through Sep 2021 stood at -$3.7 million (changed N/A YoY), while the FY2020 annual figure was -$1.7 million, changed N/A from the prior year.
Non Operating Income for Q3 2021 stood at -$328000.0, up from -$2.5 million in the prior quarter.
The five-year high for Non Operating Income was $832245.0 in Q1 2021, with the low at -$2.5 million in Q2 2021.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Op. Inc. (Qtr)
1	Vertex Pharmaceuticals	138.78 Bn	130.92 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.50 Bn	77.51 Bn	3.93 Bn	234.30 Mn
3	Argenx Se	63.51 Bn	58.32 Bn	1.37 Bn	-
4	Moderna	58.06 Bn	52.92 Bn	52.00 Mn	-
5	Revolution Medicines	44.04 Bn	44.04 Bn	-	-139.24 Mn
6	BeOne Medicines	40.04 Bn	34.94 Bn	1.53 Bn	-
7	Alnylam Pharmaceuticals	35.45 Bn	32.14 Bn	992.69 Mn	-53.64 Mn
8	Royalty Pharma	28.41 Bn	27.57 Bn	-	-51.63 Mn
9	Insmed	27.42 Bn	26.26 Bn	358.27 Mn	-
10	Surrozen	258.80 Mn	258.80 Mn	-	-

Historic Data

Download Data